Incorrect Classification of Pharmaceutical Agent | JAMA | JAMA Network
[Skip to Navigation]
Sign In
Views 2,678
Citations 0
Correction
August 12, 2021

Incorrect Classification of Pharmaceutical Agent

JAMA. 2021;326(9):873. doi:10.1001/jama.2021.14278

In the JAMA Insights article titled “Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk,” published July 20, 2021,1 there was an error in nomenclature. Inclisiran is described as an antisense olignonucleotide, which is incorrect. Inclisiran is a small interfering RNA (siRNA) molecule that interferes with translation of PCSK-9 mRNA. This article was corrected online.

References
1.
Wilkins  JT, Lloyd-Jones  DM.  Novel lipid-lowering therapies to reduce cardiovascular risk.   JAMA. 2021;326(3):266-267. doi:10.1001/jama.2021.2244PubMedGoogle ScholarCrossref
×